ARRO Day is Saturday, Sept 28 this year! Join us for a Mentorship Meet and Greet, job panels, and more! This is a great time to talk about job opportunities (for those PGY-4s), catch up with interview trail friends, and get a pulse on important topics in radonc!

Hypothetical scenario: A 48-year-old diagnosed with Stage IIIA rectal cancer, identifying as a cisgender gay man who exclusively engages in receptive anal intercourse. How will you personalize the treatment discussion? Learn more here: nature.com/articles/s4157… Nature Reviews Gastroenterology & Hepatology

Thanks to Maimonides Health for sharing our paper!

.Nature Reviews Gastroenterology & Hepatology celebrates Pride Month with a special issue that takes stock of the challenges the LGBTQ+ community continues to experience. Editorial: go.nature.com/45llrlx Browse the issue: go.nature.com/3KGrAPt

Curious about breaking the silence on taboo topics in the medical literature? Join the ACRL webinar on 6/18 at 11 AM EST. Register at shorturl.at/4Aypi And explore my favorite taboo topic in @NatRevGastro, free until 6/19! nature.com/articles/s4157…

Hey fellow journos - We just completed this massive survey into butt sex (almost 16,000 people! Thank yoooou. One of the largest on this topic.) Very excited to share the results in our episode this week. And pls get in touch if you want the presser [email protected]

Journal editors and staff are an essential component for scientific publishing. Amid the tremendous publishing costs and humungous profit margins of the publishers they should get their fair share docs.google.com/document/d/1Th… nuj.org.uk/resource/journ…

We didn’t think it would get to this but here we are #SpringerNatureStrike, find out how it came to this nuj.org.uk/resource/sprin… NUJ Nature journals NUJ

Setting aside the jokes, please check out #SpringerNatureStrike and NUJ Nature journals for what the editors behind the (real) journals are doing today

🚨 NEW EP ALERT! There's all this talk of earth-shattering orgasms from anal sex & masturbation. So we're finding out: Is the "male G-spot" real? And if so ... what does that mean for folks with different equipment down there? This one's a banger 🍆 open.spotify.com/episode/0k7oxy…

Psyched to have been given the opportunity to do more data analyses for the awesome team at Science Vs! This one was super interesting (and entertaining) - stay tuned for pub in collaboration with Daniel Dickstein Wendy Zukerman & Science Vs team!

#SpringerNatureStrike

Need a good laugh with your science?? Need a mind blowing orgasm?? 🤯🤯😶‍🌫️😎 We got you covered open.spotify.com/episode/0k7oxy…

Never imagined I'd become the anal whisperer...especially with a last name like Dickstein! Tune in to this week's Science Vs on Spotify to learn about the prostate, pudendal nerve, and pleasure: shorturl.at/tHwwp Thank you Wendy Zukerman for having me—it was a blast!

Thank you @StephenFry for signing the open letter in support of striking Springer Nature staff, joining more than 800 signatories — including 11 The Nobel Prize winners. We are beyond grateful 🙏🙏🙏

Nobel or not, thank you so much everyone for your support for the #springernaturestrike. We don’t want to be in this position, and we hope we won’t be in it much longer

Congratulations to one of our chief residents, Dr. Kristin Hsieh, on her oral presentation at the 2024 World Congress of Brachytherapy. She discussed in detail the pipeline of U.S. brachytherapists

⚡️Today FDA approved Vorasidenib for IDH-mutant low grade gliomas When patients ask you about this drug, make sure to inform them that ▶️ risk of tumor progression at 2 years is 49% with Vorasidenib (INDIGO trial) compared to 15% with chemoRT (RTOG 9802) ▶️tumors remain stable

One of our chief residents Daniel Dickstein recently discussed how to improve radiation treatment and quality of life for sexual and gender minority patients with Conquer Cancer, the ASCO Foundation conquer.org/cancer-researc…

⚡️Excited to share a new commentary by Dr. Kunal Sindhu and myself in NatureRevClinOncol on vorasidenib, the newly FDA-approved treatment for IDH-mutant low-grade gliomas. ❗️With no proven survival or quality of life benefit over standard chemoradiotherapy and serious ethical